Dr. Jonathan Edelman, MD, Vice President, Clinical Development at Seqirus discusses the Phase 3 clinical data presented at the 2021 Pediatric Academic Societies (PAS) virtual conference that supports the use of cell-based quadrivalent influenza vaccine (QIVc) in children 6 months to <4 years old. He talks about the value of cell-based vaccine technology over traditional egg-based vaccines for pediatricians, their young patients and other patient populations, how cell-based influenza vaccines are designed to produce an exact match to viral strains annually selected by the WHO (building on evidence from 100 million QIVc doses distributed globally). He also discusses the advantages of cell-based influenza technology over the standard manufacturing process in the event of a flu pandemic, being more scalable and offering faster production.
Dr. Jonathan M. Edelman is Vice President of Clinical Development at Seqirus, a Global Influenza Vaccine company, and part of the CSL group, the largest Biopharmaceutical Company headquartered in Australia and third largest in the world. At Seqirus, Jon is responsible for the clinical research on a wide portfolio of influenza vaccines including those specialized for the very young and very old, as well as the general population. In addition, Jon is responsible for Seqirus’ pandemic influenza vaccines programs in cooperation with governments around the world. Prior to joining Seqirus, Jon was the Therapeutic Area head for CLS Behring, the sister company of Seqirus, where he directed clinical research into human plasma derived products to treat many rare diseases. Jon has spent the past 27 years in the pharmaceutical industry, working first for Merck and company where he was for 17 years before moving to the CSL group.